HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Stem cell transplantation, Stem cell transplant, Haploidentical transplant
Eligibility Criteria
Inclusion Criteria: Must have one of the following diagnosis: AML in remission or relapse (e.g., FAB M7 or biphenotypic leukemia) High-risk ALL in first remission (e.g., poor responder to prednisone, Ph+ ALL) ALL beyond first remission Secondary leukemia Primary myelodysplasia (including RAEB, RAEB-T, CMML, JCML, and JMML) Chronic myeloid leukemia Histiocytoses (including multi-system Langerhans' cell histiocytosis and hemophagocytic lymphohistiocytosis Inclusion criteria Donor research participants HIV negative (date). Hepatitis B surface antigen negative (date). Hepatitis C antibody negative (date). Syphilis negative (date). Donor is equal to or greater than 3 on 6 HLA match (date). Not pregnant (negative pregnancy test). Not lactating. At least 18 years of age. Exclusion Criteria Patients greater than 24 months of age at the time of transplant. HLA-identical sibling donor is available. Cardiac function: shortening fraction <25%. Pulse oximetry oxygen saturation <92% on room air. Glomerular filtration rate less than 40 ml/min/1.73 m2 (may use Technetium-99 result for GFR). Direct bilirubin > 3 mg/dl. SGPT > 500 U/L. Patients with previous allergy to mouse proteins. Patients with previous allergy to rabbit serum products. Patients with Down's syndrome
Sites / Locations
- St. Jude Children's Research Hospital
Arms of the Study
Arm 1
Experimental
Study Participants
Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device. Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation.